NanoViricides, Inc. is a nano-biopharmaceutical company. The Company is a development-stage company with several drugs in various stages of development. The Company focuses on its research and clinical programs on specific anti-viral therapeutics. The Company is engaged in the application of nanomedicine technologies to the issues of viral diseases. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. In addition, the nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NYSEMKT:NNVC
- CUSIP: N/A
- Web: www.nanoviricides.com/
- Market Cap: $80.1 million
- Outstanding Shares: 63,071,000
- 50 Day Moving Avg: $1.32
- 200 Day Moving Avg: $1.27
- 52 Week Range: $1.03 - $1.71
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 31.75
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.35 per share
- Price / Book: 3.63
- EBIDTA: ($9,190,000.00)
- Return on Equity: -60.61%
- Return on Assets: -42.00%
- Average Volume: 76,159 shs.
- Beta: 0.44
- Short Ratio: 18.99
Frequently Asked Questions for NanoViricides (NYSEMKT:NNVC)
What is NanoViricides' stock symbol?
NanoViricides trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "NNVC."
How were NanoViricides' earnings last quarter?
NanoViricides Inc (NYSEMKT:NNVC) announced its quarterly earnings data on Wednesday, February, 25th. The company reported ($0.03) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.02. The firm earned $1.82 million during the quarter, compared to analyst estimates of $1.75 million. View NanoViricides' Earnings History.
Who are some of NanoViricides' key competitors?
Some companies that are related to NanoViricides include Recro Pharma (REPH), XBiotech (XBIT), Redhill Biopharma (RDHL), Synthetic Biologics (SYN), Summit Therapeutics PLC (SMMT), Cellular Biomedicine Group (CBMG), Adverum Biotechnologies (ADVM), Trevena (TRVN), Dimension Therapeutics (DMTX), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Axsome Therapeutics (AXSM), Agile Therapeutics (AGRX), ProQR Therapeutics N.V. (PRQR), Verona Pharma Plc (VRP), Sorrento Therapeutics (SRNE), Synthetic Biologics (SYN) and Summit Therapeutics PLC (SUMM).
Who are NanoViricides' key executives?
NanoViricides' management team includes the folowing people:
- Anil Diwan Ph.D., Chairman of the Board, President
- Eugene Seymour M.D., Chief Executive Officer, Director
- Meeta Vyas, Chief Financial Officer
- Milton Boniuk, Independent Director
- Stanley Glick CPA, Independent Director
- Mukund S. Kulkarni Ph.D., Independent Director
How do I buy NanoViricides stock?
Shares of NanoViricides can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NanoViricides' stock price today?
MarketBeat Community Rating for NanoViricides (NYSEMKT NNVC)MarketBeat's community ratings are surveys of what our community members think about NanoViricides and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of NanoViricides stock can currently be purchased for approximately $1.27.
Consensus Ratings for NanoViricides (NYSEMKT:NNVC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for NanoViricides (NYSEMKT:NNVC)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for NanoViricides (NYSEMKT:NNVC)Earnings History by Quarter for NanoViricides (NYSEMKT NNVC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/25/2015||Q215||($0.05)||($0.03)||$1.75 million||$1.82 million||View||N/A|
Earnings Estimates for NanoViricides (NYSEMKT:NNVC)
Current Year EPS Consensus Estimate: $-0.20 EPS
Next Year EPS Consensus Estimate: $0.04 EPS
Dividend History for NanoViricides (NYSEMKT:NNVC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for NanoViricides (NYSEMKT:NNVC)Insider Trades by Quarter for NanoViricides (NYSEMKT:NNVC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/22/2015||Milton Boniuk||Director||Buy||25,000||$1.30||$32,500.00|| |
|9/11/2015||Milton Boniuk||Director||Buy||50,000||$1.02||$51,000.00|| |
|8/26/2015||Milton Boniuk||Director||Buy||50,000||$1.05||$52,500.00|| |
|7/8/2015||Milton Boniuk||Director||Buy||50,000||$1.58||$79,000.00|| |
|5/20/2015||Milton Boniuk||Director||Buy||50,000||$1.60||$80,000.00|| |
|5/8/2015||Milton Boniuk||Director||Buy||405,954||$2.58||$1,047,361.32|| |
|1/12/2015||Anil Diwan||Major Shareholder||Buy||14,000||$2.56||$35,840.00|| |
|1/6/2015||Milton Boniuk||Director||Buy||25,000||$2.60||$65,000.00|| |
|12/9/2014||Milton Boniuk||Director||Buy||50,000||$3.05||$152,500.00|| |
|7/17/2014||Milton Boniuk||Director||Buy||57,144||$3.50||$200,004.00|| |
|2/20/2014||Anil Diwan||Major Shareholder||Buy||50,000||$3.61||$180,500.00|| |
|10/21/2013||Anil Diwan||Major Shareholder||Sell||142,000||$5.29||$751,180.00|| |
Headline Trends for NanoViricides (NYSEMKT:NNVC)
Latest Headlines for NanoViricides (NYSEMKT:NNVC)
|NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12, 2017|
finance.yahoo.com - September 12 at 6:34 AM
|NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin|
finance.yahoo.com - July 11 at 5:29 AM
|Pioneer Trust Bank N A Buys Altria Group Inc, Automatic Data Processing Inc, Nanoviricides Inc, ...|
www.nasdaq.com - July 8 at 1:03 PM
|NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology|
finance.yahoo.com - June 27 at 6:41 AM
|NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology|
finance.yahoo.com - June 20 at 7:44 AM
|NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City|
finance.yahoo.com - June 13 at 8:57 AM
|FDA Panel To Review PTCT's Translarna, CTIC Plunges On Offering, NNVC Abuzz|
www.rttnews.com - June 7 at 8:35 AM
|NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies|
finance.yahoo.com - June 6 at 7:35 PM
|NanoViricides Files Quarterly Report for Period Ending 2017-03-31|
finance.yahoo.com - May 17 at 8:56 AM
|NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 …|
finance.yahoo.com - April 28 at 12:29 AM
|NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles|
finance.yahoo.com - April 26 at 6:26 PM
|NanoViricides reports 2Q loss - Yahoo Finance|
finance.yahoo.com - February 17 at 8:27 AM
|NanoViricides Files Quarterly Report for Period Ending 2016-12-31|
finance.yahoo.com - February 16 at 6:24 PM
|NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising ... - PR Newswire (press release)|
www.prnewswire.com - February 14 at 9:44 PM
|NANOVIRICIDES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secur|
biz.yahoo.com - February 13 at 8:03 PM
|NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company|
finance.yahoo.com - February 13 at 9:49 AM
|NANOVIRICIDES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders|
biz.yahoo.com - December 15 at 7:47 PM